Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial
Thrombosis and Haemostasis, Volume 92, No. 3, Year 2004
Notification
URL copied to clipboard!
Description
We have conducted a prospective randomized controlled trial to evaluate the role of low-dose unfractionated heparin prophylaxis in preventing central venous line-related thrombosis in patients with haemato-oncological disease. Patients were randomly assigned to receive either prophylactic intravenous unfractionated heparin (continuous infusion of 100 IU/kg/daily) or 50 ml/daily of normal saline solution as a continuous infusion. CVLs were externalized, non tunneled, double lumen catheters. All CVLs were placed percutaneously by the same physician in the subclavian vein. Upper limb veins were systematically examined by ultrasonography just before, or <24 hours after, catheter removal, and in case of clinical signs of thrombosis. One hundred and twenty-eight CVLs were inserted. Catheter-related thrombosis occurred in 1.5% of the catheters inserted in patients of the heparin group, and in 12.6% in the control group (p = 0.03). No other risk factors were found for the development of catheter-related thrombosis. Two and three patients experienced severe bleeding in the heparin group, and in the control group, respectively (p = 0.18). There were no other side-effects clearly ascribable to the use of unfractionated heparin. This is the first prospective, randomized study, which shows that low-dose of unfractionated heparin is safe and effective to prevent catheter-related thrombosis in patients with haemato-oncological disease. © 2004 Schattauer GmbH, Stuttgart.
Authors & Co-Authors
Abdelkefi, Abderrahman
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Othman, Tarek Ben
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Kammoun, Leïla
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Chelli, M.
Tunisia, Manouba
Université de Tunis el Manar, Institut Mohamed Kassab D'orthopédie
Romdhane, Neïla Ben
Tunisia, Tunis
Hôpital la Rabta
Kriaa, A.
Tunisia, Tunis
Hôpital la Rabta
Ladeb, Saloua
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Torjman, Lamia
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Lakhal, Amel
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Achour, W.
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Ben Hassen, Assia
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Hsaïri, Mohamed
Tunisia, Tunis
Institut National de Santé Publique
Ladeb, Fethi
Tunisia, Manouba
Université de Tunis el Manar, Institut Mohamed Kassab D'orthopédie
Abdeladhim, Abdeladhim Ben
Tunisia, Tunis
Centre National de Greffe de Moelle Osseuse
Statistics
Citations: 80
Authors: 14
Affiliations: 4
Identifiers
Doi:
10.1160/TH04-02-0087
ISSN:
03406245
Study Design
Randomised Control Trial
Cohort Study
Study Approach
Quantitative